Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content

Table 2 Unanswered questions about B-cell activating factor inhibition

From: B-cell activating factor targeted therapy and lupus

Clinical

Mechanistic

Comparative efficacy of belimumab with different background immunosuppressive therapies

Secondary therapeutic effects of BAFF inhibition beyond primary effects on B cells

Belimumab utility in unstudied patient populations (pediatric lupus, nephritis, cerebritis)

Effect of BAFF inhibition on selection and maturation of naïve and antigen-activated autoreactive B cells in humans

Duration of therapeutic effect

 

Safety of belimumab post B-cell depletion

 

Utility of atacicept, LY2127399, and other BAFF/APRIL-blocking therapies

for SLE and other autoimmune diseases

 
  1. APRIL, a proliferation-inducing ligand; BAFF, B-cell activating factor; SLE, systemic lupus erythematosus.
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us